Tenofovir: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Tenofovir disoproxil fumarate''' ('''TDF''' or '''PMPA'''<ref>{{cite journal | title=Post-exposure prophylaxis for SIV revisited: Animal model for HIV infection | author=Emau P | journal=AIDS Res Ther | year=2006 | volume=3 | pages=29 | doi=10.1186/1742-6405-3-29 | pmid=17132170 | pmc=1687192 | author-separator=, | author2=Jiang Y | author3=Agy MB | display-authors=3 | last4=Tian | first4=Baoping | last5=Bekele | first5=Girma | last6=Tsai | first6=Che-Chung }}</ref>), marketed by [[Gilead Sciences]] under the trade name '''Viread''', belongs to a class of [[antiretroviral drug]]s known as nucleotide analogue [[reverse transcriptase inhibitor]]s (NRTIs), which block [[reverse transcriptase]], a crucial virus enzyme in [[HIV|human immunodeficiency virus 1 (HIV-1)]] and [[hepatitis B virus]] infections.<ref name=prescribing_info>Gilead Sciences, Inc. [http://www.gilead.com/pdf/viread_pi.pdf Prescribing Information.] Revised: November 2012.</ref> | |||
==Category== | ==Category== | ||
Antiretroviral | |||
==US Brand Names== | ==US Brand Names== | ||
| Line 26: | Line 28: | ||
'''| [[Tenofovir labels and packages|Labels and Packages]]''' | '''| [[Tenofovir labels and packages|Labels and Packages]]''' | ||
==References== | ==References== | ||
Revision as of 22:06, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Tenofovir disoproxil fumarate (TDF or PMPA[1]), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NRTIs), which block reverse transcriptase, a crucial virus enzyme in human immunodeficiency virus 1 (HIV-1) and hepatitis B virus infections.[2]
Category
Antiretroviral
US Brand Names
VIREAD®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
References
- ↑ Emau P; Jiang Y; Agy MB; et al. (2006). "Post-exposure prophylaxis for SIV revisited: Animal model for HIV infection". AIDS Res Ther. 3: 29. doi:10.1186/1742-6405-3-29. PMC 1687192. PMID 17132170. Unknown parameter
|author-separator=ignored (help) - ↑ Gilead Sciences, Inc. Prescribing Information. Revised: November 2012.